Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has announced a new Investigator-Initiated Trial (IIT) to compare the diagnostic performance of its proprietary product, 64Cu-SAR-bisPSMA, against the current standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence. The trial, known as Co-PSMA, is led by Professor Louise Emmett at St. Vincent’s Hospital, Sydney. ...
Prostate Cancer Diagnostics
Advertisement
Latest News
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Advertisement
Section Editor
Geoffrey Johnson, MD, PhDChair of the Radiopharmaceutical Trial Team | Mayo Clinic
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.